Plexiform Neurofibromas Treatment Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-31　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 1,888.0 Mn
2033 年預估規模: USD 3,265.0 Mn
年複合成長率 CAGR: 8.4%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-31頁數 152報告編號 CMI5430

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Plexiform Neurofibromas Treatment Market, By Drug Class (Selumetinib, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticonvulsants, Others (Tricyclic Antidepressants, etc.)), By Patient Population (Pediatric, Adult), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Plexiform neurofibromas is an uncommon variant of neurofibromatosis type 1 that arises from multiple nerves as bulging and deforming masses involving also connective tissue and skin folds. Neurofibromatosis is a genetic neurological disorder which can affect the skin, nerves, brain, and spinal cord. Neurofibromas or tumors, grow along the body's nerves or on or underneath the skin. There are three types of neurofibromatosis that are associated with unique symptoms and signs, Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and Schwannomatosis. Plexiform neurofibromas are essentially pathognomonic of neurofibromatosis type 1 (NF1) which is a common complication of neurofibromatosis. Plexiform neurofibromas are predominantly inherited tumors that can occur anywhere in the body. This includes the head and neck, extremities, areas around the spine and deep in the body where they may affect organs. Plexiform neurofibromas are usually diagnosed in early childhood. They are found in approximately 30% of patients with NF1. Plexiform neurofibromas diffusely involve long nerve segments and its branches, often extending beyond the epineurium into the surrounding tissue. Market Dynamics Adoption of inorganic strategies, such as product approval, by regulatory authority such as the U.S. Food and Drug Administration is expected to drive the global plexiform neurofibromas treatment market growth over the forecast period. For instance, in April 2020, AstraZeneca, a biopharmaceutical company, announced that they had received an approval from the U.S. Food and Drug Administration for Selumetinib under the brand name Koselugo, for pediatric patients, 2 years of age and older, with neurofibromatosis type 1. Selumetinib is a kinase inhibitor and the first therapy approved for pediatric patients with neurofibromatosis. Key features of the study • This report provides an in-depth analysis of the global plexiform neurofibromas treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global plexiform neurofibromas treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, SpringWorks Therapeutics, Alcaliber S.A, Teva Pharmaceutical Industries Ltd., Glenmark, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Apotex Inc., Mylan N.V., GSK plc., Solara Active Pharma Sciences Ltd., Abbott, Shanghai Kechow Pharma, Inc., Endo Pharmaceuticals Inc., Purdue Pharma L.P, Merck & Co., Inc., NFlection Therapeutics, Healx, and Array Biopharma • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global plexiform neurofibromas treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plexiform neurofibromas treatment market Market Segmentation • By Drug Class (Revenue, USD Mn, 2020 - 2033) o Selumetinib o Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) o Anticonvulsants o Others (Tricyclic Antidepressants, etc.) • By Application Insights (Revenue, USD Mn, 2020 - 2033) o Pediatric o Adult • By End User Insights (Revenue, USD Mn, 2020 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • By Region Insights (Revenue, USD Mn, 2020 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East & Africa  GCC Countries  Israel  Rest of Middle East & Africa • Key Players o AstraZeneca o Pfizer Inc. o Sun Pharmaceuticals Industries Limited o Mallinckrodt Pharmaceuticals o SpringWorks Therapeutics o Alcaliber S.A o Teva Pharmaceutical Industries Ltd. o Glenmark, Amneal Pharmaceuticals LLC o Aurobindo Pharma o Apotex Inc. o Mylan N.V. o GSK plc. o Solara Active Pharma Sciences Ltd. o Abbott o Shanghai Kechow Pharma, Inc. o Endo Pharmaceuticals Inc. o Purdue Pharma L.P. o Merck & Co., Inc. o NFlection Therapeutics o Healx o Array Biopharma

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Drug Class  Market Snapshot, By Patient Population  Market Snapshot, By Distribution Channel  Market Snapshot, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o PEST Analysis o PORTER’s Analysis o Key Developments o Brand Analysis o Merger and Collaboration Scenario o Epidemiology o Product Approvals/Launches o Treatment Algorithm o Treatment Option Analysis o Site of Activity (Mode of Action) o New Investments by Major Market Players o Manufacturer Revenue o Disease Awareness Programs o Healthcare Spending by Country 4. Global Plexiform Neurofibromas Treatment Market, By Drug Class, 2020–2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2020–2033  Segment Trends o Selumetinib  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Anticonvulsants  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Others (Tricyclic Antidepressants, etc.)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) 5. Global Plexiform Neurofibromas Treatment Market, By Patient Population, 2020–2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2020–2033  Segment Trends o Pediatric  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Adult  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) 6. Global Plexiform Neurofibromas Treatment Market, By Distribution Channel, 2020–2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2020–2033  Segment Trends o Hospital Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Retail Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Online Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) 7. Global Plexiform Neurofibromas Treatment Market, By Region, 2020–2033, (USD Mn) o Introduction  Market Share Analysis, By Region, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, For Regions, 2020–2033  Regional Trends o North America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2033, (USD Mn) o U.S.  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Canada  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Latin America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2033, (USD Mn) o Brazil  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Mexico  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Argentina  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Rest of Latin America  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Europe  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2033, (USD Mn) o U.K.  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Germany  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Italy  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o France  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Spain  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Russia  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Rest of Europe  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2033, (USD Mn) o China  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o India  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Japan  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o ASEAN  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Australia  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o South Korea  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Rest of Asia Pacific  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2033, (USD Mn) o GCC  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Israel  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Rest of Middle East  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Africa  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020–2033, (USD Mn) o North Africa  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o Central Africa  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) o South Africa  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn) 8. Competitive Landscape o AstraZeneca  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Pfizer Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Sun Pharmaceuticals Industries Limited  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Mallinckrodt Pharmaceuticals  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o SpringWorks Therapeutics  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Alcaliber S.A  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Teva Pharmaceutical Industries Ltd.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Glenmark  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Amneal Pharmaceuticals LLC  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Aurobindo Pharma  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Apotex Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Mylan N.V.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o GSK plc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Solara Active Pharma Sciences Ltd.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Abbott  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Shanghai Kechow Pharma, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Endo Pharmaceuticals Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Purdue Pharma L.P  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Merck & Co., Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o NFlection Therapeutics  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Healx  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Array Biopharma  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies 9. Section o Research Methodology o About Us *Browse 113 market data tables and 50 figures on Global Plexiform Neurofibromas Treatment Market” - forecast to 2033

提及公司

AstraZenecaPfizer Inc.Sun Pharmaceuticals Industries LimitedMallinckrodt PharmaceuticalsSpringWorks TherapeuticsAlcaliber S.ATeva Pharmaceutical Industries Ltd.Glenmark, Amneal Pharmaceuticals LLCAurobindo PharmaApotex Inc.Mylan N.V.GSK plc.Solara Active Pharma Sciences Ltd.AbbottShanghai Kechow Pharma, Inc.Endo Pharmaceuticals Inc.Purdue Pharma L.P.Merck & Co., Inc.NFlection TherapeuticsHealxArray Biopharma

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們